预约演示
更新于：2025-11-23
Dexamethasone Palmitate
地塞米松棕榈酸酯
更新于：2025-11-23
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1988-01-20), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C38H59FO6 |
InChIKeyWDPYZTKOEFDTCU-WDJQFAPHSA-N |
CAS号14899-36-6 |
关联
23
项与 地塞米松棕榈酸酯 相关的临床试验NCT06997419
Intravenous Dexamethasone Palmitate for Prophylaxis of Postoperative Nausea and Vomiting After Open Surgery
ChiCTR2500104894
Interlaminar epidural platelet rich plasma versus epidural steroid injection for acute herpes zoster: a prospective clinical evaluation
NCT06988124
Intravenous Dexamethasone Palmitate for Prophylaxis of Postoperative Nausea and Vomiting After Craniotomy
100 项与 地塞米松棕榈酸酯 相关的临床结果
登录后查看更多信息
100 项与 地塞米松棕榈酸酯 相关的转化医学
登录后查看更多信息
100 项与 地塞米松棕榈酸酯 相关的专利（医药）
登录后查看更多信息
110
项与 地塞米松棕榈酸酯 相关的文献（医药）2025-11-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Intratympanic delivery of dexamethasone palmitate-loaded lipid nanoparticles in dual viscosity hyaluronic acids hydrogel for prolonged retention and hearing loss treatment
Article
作者: Suh, Myung-Whan ; Noh, Ha-Yeon ; Zeb, Alam ; Choi, Ho-Ik ; Bae, Yumi ; Noh, Tae-Soo ; Ryu, Jeong-Su ; Kim, Jin-Ki ; Hwang, Yu-Jung
In this study, dexamethasone palmitate (DXP)-loaded solid lipid nanoparticles (DXP-SLNs) were incorporated into a dual-viscosity hyaluronic acids mixture-based hydrogel (DXP-SLNs DHA-gel) to prolong retention and improve hearing outcomes in ototoxic hearing loss. The optimized DXP-SLNs, formulated with DXP, stearyl alcohol, Tween 60, Span 60, and Myrj S40 at 1/1/1.2/0.2/5 (w/w ratios), showed a small particle size (125.3 nm), narrow PDI (0.289), adequate zeta potential (-24.6 mV), and high encapsulation efficiency (98.7 %). DXP-SLNs exhibited sustained in vitro drug release in artificial perilymph and mouse plasma. The DXP-SLNs DHA-gel also demonstrated favorable viscoelastic and flow properties for convenient injectability. After intratympanic administration to rats with ototoxic hearing loss, DXP-SLNs DHA-gel improved hearing ability, as demonstrated by lower auditory brainstem response thresholds at 8, 16, and 32 kHz frequencies compared to dexamethasone disodium phosphate solution (Dex-saline). Endoscopic examination revealed the biocompatibility and safety of the DXP-SLNs DHA-gel, as evidenced by recovery of the tympanic membrane without signs of inflammation or permanent perforation within 14 days. Furthermore, DXP-SLNs DHA-gel showed prolonged retention in the middle ear compared to Dex-saline (7.1 vs. < 1 day). Taken together, DXP-SLNs DHA-gel with enhanced therapeutic efficacy could be a promising intratympanic formulation for the treatment of auditory disorders.
2025-08-01REGIONAL ANESTHESIA AND PAIN MEDICINE
Therapeutic effect of epidural dexamethasone palmitate in a rat model of lumbar spinal stenosis
Article
作者: Zheng, Haiyan ; Choi, Eun Joo ; Choe, Ghee Young ; Nahm, Francis Sahngun ; LI, Mei Hui ; Lee, Pyung Bok
Background:
Dexamethasone palmitate (DEP), a prodrug of dexamethasone (DEX), is a synthetic corticosteroid medication distinguished by the inclusion of a fatty acid component known as palmitate. This study introduces DEP as a novel therapeutic option for spinal epidural injection, aiming to provide safer and longer-lasting pain relief as an alternative to for patients with spinal stenosis.
Methods:
40 rats were randomly divided into four groups: those receiving epidural administration of normal saline (NS), and DEP in the lumbar spinal stenosis (LSS) model, and non-model rats receiving epidural NS administration. Paw withdrawal thresholds to mechanical stimulation and motor function (neurogenic intermittent claudication) were observed for up to 21 days. Hematology and blood chemistry analyses were performed 1 week after drug therapy. Tissue samples were collected for steroid pathology examination to evaluate adhesion degree, perineural area inflammation, and chromatolysis in the dorsal root ganglion (DRG), and adrenal gland.
Results:
The DEX and DEP groups demonstrated significant recovery from mechanical allodynia and motor dysfunction after 2 weeks of drug therapy (p<0.001). However, by the third week, the effect of DEX started to diminish while the effect of DEP persisted. Furthermore, the DEP group exhibited reduced fibrosis and less chromatolysis than the NS group. No steroid overdose or toxin was observed in any group.
Conclusion:
The epidural administration of DEP demonstrated therapeutic efficacy in reducing allodynia and hyperalgesia resulting from chronic DRG compression, thus offering prolonged pain relief. These findings underscore the potential of DEP as a promising treatment alternative for pain associated with LSS, serving as a viable substitute for .
2025-04-01LUPUS
Anifrolumab for refractory cutaneous lupus lesions in pediatric systemic lupus erythematosus
Article
作者: Mori, Masaaki ; Shimbo, Asami ; Shmizu, Masaki ; Kaneko, Shuya ; Hayashi, Yuko ; Miyaoka, Futaba ; Irabu, Hitoshi ; Akutsu, Yuko ; Akamine, Keiji ; Hatano, Maho
Type I interferon (IFN) plays an important role in the pathogenesis of systemic lupus erythematosus (SLE) and cutaneous manifestations. Anifrolumab, a fully humanized monoclonal antibody against type 1 IFN receptor, has shown a significant reduction of the disease activity of SLE and cutaneous manifestations in adults. We reported two pediatric SLE patients with refractory cutaneous lesions that dramatically improved after anifrolumab therapy. This is the first study to show clinical effects of anifrolumab for pediatric SLE patients. These cases suggest the efficacy of anifrolumab for pediatric SLE patients with refractory cutaneous lesions and elevated IFN levels.
100 项与 地塞米松棕榈酸酯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 类风湿关节炎 | 日本 | 1988-01-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 膝关节炎 | 临床3期 | 中国 | 2025-01-22 | |
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2008-04-01 | |
| 眼部疾病 | 临床前 | 以色列 | 2025-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用